Patient-specific quality assurance (QA) is critical in cancer treatments as it improves treatment outcomes and reduces the risk of complications. As cancer treatments become more and more complex, the need for equally advanced QA solutions grows. The Delta4 family of products is well-positioned to meet these changing needs.

ScandiDos has seen considerable demand for its products in China in the last two quarters. The growing business is attributed to the increasing need for advanced radiotherapy treatment technologies to handle the booming cancer patient population. Dominated by the Delta4 Phantom+, the Delta4 Family of products has become the preferred choice for more than 100 hospitals in China.

ScandiDos is working closely with its distributor HGPT to develop the Chinese market further. This collaboration has helped ScandiDos to establish a strong foothold in the market and demonstrates ScandiDos' commitment to providing customers world-wide with the highest quality of services. The Chinese market's potential for future growth, combined with the increasing demand for patient-specific QA solutions, positions ScandiDos for continued success in the coming years.

"We are thrilled to see this growing demand for our products in China," says Gustaf Piehl, CEO of ScandiDos. “The Delta4 products are well-suited to meet the needs of the Chinese healthcare providers and we are committed to continue to develop and grow in this market. The response from the Chinese market is a promising sign of continued success in the coming years."